Human Monoclonal Antibodies Against Hendra and Nipah Viruses

Abstract

The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

What is claimed is: 
     
         1 . A substantially pure polypeptide comprising an antibody selectively binding a Hendra or Nipah G glycoprotein epitope, wherein said antibody includes a heavy chain CDR3 region having the amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 39, SEQ ID NO: 55, SEQ ID NO: 71, SEQ ID NO: 87, SEQ ID NO: 103, SEQ ID NO: 119, SEQ ID NO: 135, SEQ ID NO: 151, SEQ ID NO: 167, SEQ ID NO: 183, SEQ ID NO: 199, SEQ ID NO: 215, SEQ ID NO: 231, SEQ ID NO: 247, SEQ ID NO: 263, SEQ ID NO: 279, SEQ ID NO: 295, SEQ TD NO: 311, SEQ ED NO: 327, SEQ ED NO: 343, SEQ ID NO: 359, SEQ ID NO: 375, SEQ ID NO: 391 and SEQ ID NO: 407. 
     
     
         2 . The substantially pure polypeptide of  claim 1  wherein said antibody comprises an Fd fragment. 
     
     
         3 . The substantially pure polypeptide of  claim 1  wherein said antibody comprises an Fab fragment. 
     
     
         4 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a heavy chain CDR2 region having the amino acid sequence of:
 a) SEQ DD NO: 5 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 21 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 37 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 53 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ DD NO: 69 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 85 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 101 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 117 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ DD NO: 133 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ JD NO: 149 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 165 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 181 (when heavy chain CDR3 region is SEQ DD NO: 183), 
 m) SEQ DD NO: 197 (when heavy chain CDR3 region is SEQ DD NO: 199), 
 n) SEQ DD NO: 213 (when heavy chain CDR3 region is SEQ DD NO: 215), 
 o) SEQ DD NO: 229 (when heavy chain CDR3 region is SEQ DD NO: 231), 
 p) SEQ ID NO: 245 (when heavy chain CDR3 region is SEQ DD NO: 247), 
 q) SEQ DD NO: 261 (when heavy chain CDR3 region is SEQ DD NO: 263), 
 r) SEQ E) NO: 277 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ TD NO: 293 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ E) NO: 309 (when heavy chain CDR3 region is SEQ E) NO: 311), 
 u) SEQ E) NO: 325 (when heavy chain CDR3 region is SEQ E) NO: 327), 
 v) SEQ E) NO: 341 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ E) NO: 357 (when heavy chain CDR3 region is SEQ E) NO: 359), 
 x) SEQ E) NO: 373 (when heavy chain CDR3 region is SEQ E) NO: 375), 
 y) SEQ E) NO: 389 (when heavy chain CDR3 region is SEQ E) NO: 391), or 
 z) SEQ ID NO: 405 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         5 . The substantially pure polypeptide of  claim 4  wherein said antibody includes a heavy chain CDR1 region having the amino acid sequence of:
 a) SEQ E) NO: 3 (when heavy chain CDR3 region is SEQ E) NO: 7), 
 b) SEQ E) NO: 19 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ E) NO: 35 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ E) NO: 51 (when heavy chain CDR3 region is SEQ E) NO: 55), 
 e) SEQ E) NO: 61 (when heavy chain CDR3 region is SEQ E) NO: 71), 
 f) SEQ E) NO: 83 (when heavy chain CDR3 region is SEQ E) NO: 87), 
 g) SEQ E) NO: 99 (when heavy chain CDR3 region is SEQ E) NO: 103), 
 h) SEQ E) NO: 115 (when heavy chain CDR3 region is SEQ E) NO: 119), 
 i) SEQ E) NO: 131 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ E) NO: 147 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ E) NO: 163 (when heavy chain CDR3 region is SEQ E) NO: 167), 
 l) SEQ E) NO: 179 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ E) NO: 195 (when heavy chain CDR3 region is SEQ E) NO: 199), 
 n) SEQ E) NO: 211 (when heavy chain CDR3 region is SEQ E) NO: 215), 
 o) SEQ E) NO: 227 (when heavy chain CDR3 region is SEQ E) NO: 231), 
 p) SEQ E) NO: 243 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ E) NO: 259 (when heavy chain CDR3 region is SEQ E) NO: 263), 
 r) SEQ E) NO: 275 (when heavy chain CDR3 region is SEQ E) NO: 279), 
 s) SEQ E) NO: 291 (when heavy chain CDR3 region is SEQ TD NO: 295), 
 t) SEQ E) NO: 307 (when heavy chain CDR3 region is SEQ TD NO: 311), 
 u) SEQ E) NO: 323 (when heavy chain CDR3 region is SEQ TD NO: 327), 
 v) SEQ ID NO: 339 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 355 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 371 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 387 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 403 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         6 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a heavy chain Fd region including the amino acid sequence of:
 a) SEQ ID NO: 1 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ED NO: 17 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 33 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 49 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 65 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 81 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 97 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 113 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 129 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 145 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 161 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 177 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 193 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 209 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 225 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 241 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 257 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 273 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 289 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 305 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 321 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 337 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 353 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 369 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 385 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 401 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         7 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a light chain CDR3 region having the amino acid sequence of:
 a) SEQ ID NO: 15 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 31 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ DD NO: 47 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 63 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 79 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 95 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 111 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 127 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 143 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 159 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 175 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 191 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 207 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 223 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 239 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 255 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 271 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 287 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 303 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 319 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 335 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 351 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 367 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 383 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 399 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 415 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         8 . The substantially pure polypeptide of  claim 7  wherein said antibody includes a light chain CDR2 region having the amino acid sequence of:
 a) SEQ ID NO: 13 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 29 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 45 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 61 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 77 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ E) NO: 93 (when heavy chain CDR3 region is SEQ E) NO: 87), 
 g) SEQ ID NO: 109 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 125 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 141 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 157 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ E) NO: 173 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 189 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ E) NO: 205 (when heavy chain CDR3 region is SEQ E) NO: 199), 
 n) SEQ E) NO: 221 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ E) NO: 237 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ E) NO: 253 (when heavy chain CDR3 region is SEQ E) NO: 247), 
 q) SEQ E) NO: 269 (when heavy chain CDR3 region is SEQ E) NO: 263), 
 r) SEQ E) NO: 285 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ E) NO: 301 (when heavy chain CDR3 region is SEQ E) NO: 295), 
 t) SEQ E) NO: 317 (when heavy chain CDR3 region is SEQ E) NO: 311), u) SEQ E) NO: 333 (when heavy chain CDR3 region is SEQ E) NO: 327), 
 v) SEQ E) NO: 349 (when heavy chain CDR3 region is SEQ E) NO: 343), 
 w) SEQ E) NO: 365 (when heavy chain CDR3 region is SEQ TD NO: 359), 
 x) SEQ E) NO: 381 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ E) NO: 397 (when heavy chain CDR3 region is SEQ E) NO: 391), or 
 z) SEQ E) NO: 413 (when heavy chain CDR3 region is SEQ E) NO: 407). 
 
     
     
         9 . The substantially pure polypeptide of  claim 8  wherein said antibody includes a light chain CDR1 region having the amino acid sequence of:
 a) SEQ E) NO: 11 (when heavy chain CDR3 region is SEQ E) NO: 7), 
 b) SEQ E) NO: 27 (when heavy chain CDR3 region is SEQ E) NO: 23), 
 c) SEQ ID NO: 43 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 59 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 75 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 91 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ID NO: 107 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 123 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 139 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 155 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 171 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 187 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 203 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 219 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 235 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 251 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 267 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 283 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 299 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 315 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 331 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 347 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 363 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 379 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 395 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 411 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         10 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a light chain region including the amino acid sequence of:
 a) SEQ ID NO: 9 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 25 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 41 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ ID NO: 57 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ ID NO: 73 (when heavy chain CDR3 region is SEQ ID NO: 71), 
 f) SEQ ID NO: 89 (when heavy chain CDR3 region is SEQ ID NO: 87), 
 g) SEQ ED NO: 105 (when heavy chain CDR3 region is SEQ ID NO: 103), 
 h) SEQ ID NO: 121 (when heavy chain CDR3 region is SEQ ID NO: 119), 
 i) SEQ ID NO: 137 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ ID NO: 153 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 169 (when heavy chain CDR3 region is SEQ ID NO: 167), 
 l) SEQ ID NO: 185 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 201 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 217 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 233 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 249 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 265 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 281 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 297 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 313 (when heavy chain CDR3 region is SEQ ED NO: 311), 
 u) SEQ ID NO: 329 (when heavy chain CDR3 region is SEQ TD NO: 327), 
 v) SEQ ID NO: 345 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 361 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 377 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 393 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 409 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         11 . The substantially pure polypeptide of  claim 1  wherein said antibody includes a heavy chain Fd region including the CDR amino acid sequences of:
 a) SEQ ID NO: 1 (when heavy chain CDR3 region is SEQ ID NO: 7), 
 b) SEQ ID NO: 17 (when heavy chain CDR3 region is SEQ ID NO: 23), 
 c) SEQ ID NO: 33 (when heavy chain CDR3 region is SEQ ID NO: 39), 
 d) SEQ DD NO: 49 (when heavy chain CDR3 region is SEQ DD NO: 55), 
 e) SEQ DD NO: 65 (when heavy chain CDR3 region is SEQ DD NO: 71), 
 f) SEQ DD NO: 81 (when heavy chain CDR3 region is SEQ DD NO: 87), 
 g) SEQ DD NO: 97 (when heavy chain CDR3 region is SEQ DD NO: 103), 
 h) SEQ DD NO: 113 (when heavy chain CDR3 region is SEQ DD NO: 119), 
 l) SEQ DD NO: 129 (when heavy chain CDR3 region is SEQ DD NO: 135), 
 j) SEQ DD NO: 145 (when heavy chain CDR3 region is SEQ ID NO: 151), 
 k) SEQ ID NO: 161 (when heavy chain CDR3 region is SEQ E) NO: 167), 
 l) SEQ ID NO: 177 (when heavy chain CDR3 region is SEQ ID NO: 183), 
 m) SEQ ID NO: 193 (when heavy chain CDR3 region is SEQ ID NO: 199), 
 n) SEQ ID NO: 209 (when heavy chain CDR3 region is SEQ ID NO: 215), 
 o) SEQ ID NO: 225 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 241 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 257 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 273 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 289 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 305 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 321 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 337 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 353 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 369 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 385 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 401 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         12 . The substantially pure polypeptide of  claim 11  wherein said antibody includes a light chain region including the CDR amino acid sequences of:
 a) SEQ ID NO: 9 (when heavy chain CDR3 region is SEQ E) NO: 7), 
 b) SEQ E) NO: 25 (when heavy chain CDR3 region is SEQ E) NO: 23), 
 c) SEQ E) NO: 41 (when heavy chain CDR3 region is SEQ E) NO: 39), 
 d) SEQ E) NO: 57 (when heavy chain CDR3 region is SEQ ID NO: 55), 
 e) SEQ E) NO: 73 (when heavy chain CDR3 region is SEQ E) NO: 71), 
 f) SEQ E) NO: 89 (when heavy chain CDR3 region is SEQ E) NO: 87), 
 g) SEQ E) NO: 105 (when heavy chain CDR3 region is SEQ E) NO: 103), 
 h) SEQ E) NO: 121 (when heavy chain CDR3 region is SEQ E) NO: 119), 
 i) SEQ E) NO: 137 (when heavy chain CDR3 region is SEQ ID NO: 135), 
 j) SEQ E) NO: 153 (when heavy chain CDR3 region is SEQ E) NO: 151), 
 k) SEQ E) NO: 169 (when heavy chain CDR3 region is SEQ E) NO: 167), 
 l) SEQ E) NO: 185 (when heavy chain CDR3 region is SEQ E) NO: 183), 
 m) SEQ E) NO: 201 (when heavy chain CDR3 region is SEQ E) NO: 199), 
 n) SEQ E) NO: 217 (when heavy chain CDR3 region is SEQ E) NO: 215), 
 o) SEQ DD NO: 233 (when heavy chain CDR3 region is SEQ ID NO: 231), 
 p) SEQ ID NO: 249 (when heavy chain CDR3 region is SEQ ID NO: 247), 
 q) SEQ ID NO: 265 (when heavy chain CDR3 region is SEQ ID NO: 263), 
 r) SEQ ID NO: 281 (when heavy chain CDR3 region is SEQ ID NO: 279), 
 s) SEQ ID NO: 297 (when heavy chain CDR3 region is SEQ ID NO: 295), 
 t) SEQ ID NO: 313 (when heavy chain CDR3 region is SEQ ID NO: 311), 
 u) SEQ ID NO: 329 (when heavy chain CDR3 region is SEQ ID NO: 327), 
 v) SEQ ID NO: 345 (when heavy chain CDR3 region is SEQ ID NO: 343), 
 w) SEQ ID NO: 361 (when heavy chain CDR3 region is SEQ ID NO: 359), 
 x) SEQ ID NO: 377 (when heavy chain CDR3 region is SEQ ID NO: 375), 
 y) SEQ ID NO: 393 (when heavy chain CDR3 region is SEQ ID NO: 391), or 
 z) SEQ ID NO: 409 (when heavy chain CDR3 region is SEQ ID NO: 407). 
 
     
     
         13 . An isolated nucleic acid comprising a nucleotide sequence encoding the polypeptide of  claim 1 . 
     
     
         14 . An isolated nucleic acid as in  claim 13  wherein said nucleic acid comprises a vector including a regulatory sequence operably joined to said nucleic acid. 
     
     
         15 . A host cell including a vector comprising a nucleic acid of  claim 13 . 
     
     
         16 . A pharmaceutical preparation comprising a pharmaceutically acceptable carrier and the polypeptide of  claim 1 . 
     
     
         17 . A diagnostic preparation comprising a pharmaceutically acceptable carrier and the polypeptide of  claim 1 . 
     
     
         18 . A method for the treatment of Hendra Virus Disease or Nipah Virus Disease comprising
 administering to a patient a therapeutically effective amount of the pharmaceutical preparation of  claim 16 .   
     
     
         19 . A method for prophylaxis against Hendra Virus Disease or Nipah Virus Disease comprising
 administering to a patient a prophylactically effective amount of the pharmaceutical preparation of  claim 16 .   
     
     
         20 . A substantially pure polypeptide comprising a monoclonal antibody that binds the antigen to which an antibody selectively binding a Hendra or Nipah G glycoprotein epitope binds, wherein said antibody includes a heavy chain CDR3 region having the amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 39, SEQ ID NO: 55, SEQ ID NO: 71, SEQ ID NO: 87, SEQ ID NO: 103, SEQ ID NO: 119, SEQ ID NO: 135, SEQ ID NO: 151, SEQ ID NO: 167, SEQ ID NO: 183, SEQ ID NO: 199, SEQ ID NO: 215, SEQ ID NO: 231, SEQ ID NO: 247, SEQ ID NO: 263, SEQ ID NO: 279, SEQ ID NO: 295, SEQ ID NO: 311, SEQ ID NO: 327, SEQ ID NO: 343, SEQ ID NO: 359, SEQ ID NO: 375, SEQ ID NO: 391 and SEQ ID NO: 407.